Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Up 6.2% – Should You Buy?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares rose 6.2% during mid-day trading on Tuesday . The company traded as high as $130.86 and last traded at $131.20. Approximately 373,398 shares traded hands during trading, a decline of 27% from the average daily volume of 508,440 shares. The stock had previously closed at $123.51.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent research reports. TD Cowen cut their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Piper Sandler restated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Price Performance

The company has a market capitalization of $7.83 billion, a price-to-earnings ratio of 18.23, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. The company has a 50-day moving average price of $122.52 and a 200-day moving average price of $116.53. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have sold 5,053 shares of company stock worth $617,442. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in JAZZ. Wedge Capital Management L L P NC bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at about $32,497,000. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the period. Cinctive Capital Management LP bought a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares in the last quarter. Finally, GW&K Investment Management LLC grew its stake in shares of Jazz Pharmaceuticals by 26.6% in the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock valued at $57,142,000 after acquiring an additional 97,589 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.